64173-00-8Relevant articles and documents
Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them
-
, (2008/12/07)
Compounds of formula (I): wherein A represents a 5, 6 or 7-membered (hetero)aromatic or non-aromatic ring,n and n′ represent 0, 1 or 2X represents an alkylene chain as defined in the description,R3 represents an aryl or heteroaryl group,one of the groups R1 and R2 represents a hydrogen atom and the other represents a group of formula (II) as defined in the description. Medicinal products containing the same which are useful in treating conditions involving a defect in apoptosis.
Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-Tetrahydro-1H-pyrazino[1,2-a]quinozalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino [1,2-,a] quinoxalines
Welmaker, Gregory S.,Nelson, James A.,Sabalski, Joan E.,Sabb, Annmarie L.,Potoski, John R.,Graziano, Denise,Kagan, Michael,Coupet, Joseph,Dunlop, John,Mazandarani, Hossein,Rosenzweig-Lipson, Sharon,Sukoff, Stacey,Zhang, Yingxin
, p. 1991 - 1994 (2007/10/03)
A series of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro- 1H-pyrazino[1,2-a]-quinoxalines was shown to exhibit 5-HT(2C) agonist binding and functional activity. Compound 21R inhibited food intake over 2 h in fasted, male Sprague-Dawley rats with ED50 values of 2 mg/kg (ip) and 10 mg/kg (po). (C) 2000 Elsevier Science Ltd.